<DOC>
	<DOCNO>NCT02441946</DOCNO>
	<brief_summary>The purpose study evaluate biological effect abemaciclib combination anastrozole compare effect abemaciclib alone anastrozole alone tumor postmenopausal woman hormone receptor positive ( HR+ ) , human epidermal growth factor receptor 2 ( HER2 ) negative breast cancer .</brief_summary>
	<brief_title>A Neoadjuvant Study Abemaciclib ( LY2835219 ) Postmenopausal Women With Hormone Receptor Positive , HER2 Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Loperamide</mesh_term>
	<mesh_term>Antidiarrheals</mesh_term>
	<criteria>Have postmenopausal status . Adenocarcinoma breast . Breast tumor â‰¥1 centimeter ( cm ) diameter , HR+ , HER2 . Neoadjuvant endocrine monotherapy deem suitable therapy . Primary breast cancer suitable baseline core biopsy . Have adequate organ function . Bilateral invasive breast cancer . Metastatic breast cancer ( local spread axillary lymph node permit ) . Inflammatory breast cancer . Prior systemic therapy radiotherapy invasive noninvasive breast cancer breast currently treat . Prior radiotherapy ipsilateral chest wall malignancy . Prior antiestrogen therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>cyclin-dependent kinase ( CDK ) 4/6 inhibitor</keyword>
	<keyword>CDK 4 6 inhibitor</keyword>
</DOC>